Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

HCl is ongoing and patients are being enrolled at 36 investigational sites worldwide.  A majority of the planned 60 subjects have been enrolled in the study. The Company expects to complete enrollment in the first half of 2011 and to report top line results from this study in the second half of 2011.

Amicus and GSK intend to commence an additional Phase 3 study (Study 012) in the first quarter of 2011. Study 012 will be an 18-month, randomized, open-label study comparing migalastat HCl to enzyme replacement therapy (ERT) in approximately 60 subjects. The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).

About Fabry DiseaseFabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A). The role of alpha-Gal A within the body is to break down a complex lipid called globotriaosylceramide (GL-3). Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. This accumulation of GL-3 is believed to cause the various symptoms of Fabry disease, including pain, kidney failure, and increased risk of heart attack and stroke.

It is currently estimated that Fabry disease affects approximately 5,000 to 10,000 people worldwide.

About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... 2011 Fiscal Year Guidance -- HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... DIEGO, Sept. 14 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its North American and European fidaxomicin Phase ... difficile infection (CDI) was presented at the ... Chemotherapy (ICAAC) in Boston. (Logo: ...
... (Nasdaq: IPHS ), a leading North American specialty ... will address the 2010 Oppenheimer Industrials Conference in New York ...   To access a live or replay webcast ... Relations Events section.  The replay will be available until December ...
Cached Biology Technology:Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 2Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 3Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 4Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 5Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 6Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 7
(Date:7/10/2014)... Ouagadougou, Burkina Faso, July 10, 2014Women in the ... to an additional family planning option. Sayana Press ... at all levels of the health system and ... a widely used contraceptivePfizer,s Depo-Provera (depot medroxyprogesterone acetate)with ... is the first of four African countries expected ...
(Date:7/9/2014)... by Caesarean section have a different intestinal flora than children ... this is the case and what it means for the ... Sciences therefore decided to scrutinise the impact of birth on ... newborn mouse pups. , The study shows ... number of cells that strengthen the immune system, says Camilla ...
(Date:7/9/2014)... hunts in Indiana state parks have helped restore the ... by overabundant populations of white-tailed deer, a Purdue study ... associate professor of forest ecology, found that a 17-year-long ... in state parks has successfully spurred the regrowth of ... browsing deer. , Jenkins said that while hunting ...
Breaking Biology News(10 mins):Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3Mouse study: Natural birth may strengthen the immune system 2Hunting gives deer-damaged forests in state parks a shot at recovery 2
... Gutenberg University Mainz (JGU) in Germany have discovered that ... barnacles, bacteria, and algae on surfaces in contact with ... platforms. Their experiments showed that steel plates to which ... applied could be exposed to seawater for weeks without ...
... R.I. [Brown University] What makes laparoscopic surgery "minimally invasive" ... makes it visually constraining. As they work on different tasks, ... could control a separate view best suited to the specific ... and his team of co-authors at Brown University and Hasbro ...
... Tokyo, July 2, 2012 - RIKEN and Fujitsu today announced ... been completed as of June 29. The K computer will ... environment settings, adjustments, and user registration. It is due to ... of September. Background Working together under ...
Cached Biology News:Paints and coatings containing bactericidal agent nanoparticles combat marine fouling 2Paints and coatings containing bactericidal agent nanoparticles combat marine fouling 3Individual perspectives improve laparoscopy 2Individual perspectives improve laparoscopy 3RIKEN and Fujitsu complete operational testing of the K computer 2RIKEN and Fujitsu complete operational testing of the K computer 3
... Human Genetic Cell Bank Service The ... based on Epstein-Barr Virus (EBV) immortalisation of ... the production of lymphoblastoid cell lines (LCLs). ... a renewable and expandable source of genomic ...
... identification through targeting resequencing. This ... assay validation/optimization, high throughput PCR setup ... samples and sequence alignment and analysis.,Agencourts ... and highly accurate identification of SNP ...
... Luciferase-based ENGENISTM (Entire Gene/cDNA or Isolated ... provide a quantitative approach for evaluation of ... serve as an efficient target for RNA ... algorithms are not perfect, leaving the probability ...
... Stabilizer is a is a bovine protein-free ... product is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2. ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ...
Biology Products: